Jefferies maintains a buy rating on AstraZeneca, highlighting that detailed data on its lung drug tozorakimab, due on 8 September, could offset the impact of a failed heart trial. The lung drug targets IL-33, potentially benefiting a broader COPD patient group than existing treatments by working regardless of eosinophil levels. Jefferies projects peak sales exceeding $5 billion beyond 2030, significantly higher than consensus estimates, emphasizing tozorakimab's commercial potential despite recent setbacks in AstraZeneca's pipeline.
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
Jefferies maintains a buy rating on AstraZeneca, expecting detailed data on its lung drug tozorakimab in September to compensate for a recent heart trial failure. The failed CARDIO-TTRansform study cut $4 billion from forecasts, but Jefferies believe...
Royalty Pharma has acquired a royalty interest from Neurimmune in AstraZeneca’s cliramitug, a Phase 3 drug targeting ATTR-CM, for up to $425 million including $125 million upfront. Cliramitug is designed to remove amyloid deposits in the heart, poten...
President Donald Trump announced that generic drugs imported into the US will continue to have zero tariffs for two more years starting August 1, 2024. After this period, tariffs will rise to 100% for one year and then 200% thereafter. The policy aim...
